Caprylates

Derivatives of caprylic acid. Included under this heading are a broad variety of acid forms, salts, esters, and amides that contain a carboxy terminated eight carbon aliphatic structure.

Also Known As:

Networked: 33 relevant articles (1 outcomes, 9 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Bril, Vera: 6 articles (01/2019 - 02/2008)
2.	Hanna, Kim: 6 articles (01/2018 - 02/2008)
3.	Dalakas, Marinos C: 5 articles (02/2012 - 02/2008)
4.	Deng, Chunqin: 5 articles (02/2012 - 02/2008)
5.	Hartung, Hans-Peter: 5 articles (02/2012 - 02/2008)
6.	Donofrio, Peter: 4 articles (02/2012 - 02/2008)
7.	Merkies, Ingemar S J: 4 articles (02/2012 - 02/2008)
8.	Hughes, Richard A C: 4 articles (10/2010 - 02/2008)
9.	ICE Study Group: 4 articles (10/2010 - 02/2008)
10.	Latov, Norman: 4 articles (10/2010 - 02/2008)

Related Diseases

1.	Primary Immunodeficiency Diseases 09/01/2003 - "Comparison of the efficacy of IGIV-C, 10% (caprylate/chromatography) and IGIV-SD, 10% as replacement therapy in primary immune deficiency. " 01/01/2016 - "This phase 4, multicenter, open-labeled, single-sequence, crossover study in pediatric patients (ages 2 to 16) with primary immunodeficiency disease (PID) evaluated the pharmacokinetics, safety, and tolerability for subcutaneously (SC) administered 10 % caprylate/chromatography purified human immune globulin injection (IGIV-C, GAMUNEX®) compared with intravenously (IV) administered IGIV-C. " 01/01/2016 - "Pharmacokinetics, Safety, and Tolerability of Subcutaneous Immune Globulin Injection (Human), 10 % Caprylate/Chromatography Purified (GAMUNEX®-C) in Pediatric Patients with Primary Immunodeficiency Disease." 09/01/2010 - "Pharmacokinetics and safety of subcutaneous immune globulin (human), 10% caprylate/chromatography purified in patients with primary immunodeficiency disease." 09/01/2010 - "An open-label, pharmacokinetic trial (n = 32) determined the non-inferiority of the subcutaneous versus intravenous route of 10% caprylate/chromatography purified human immune globulin intravenous (IGIV-C; Gamunex®) administration by comparing the steady-state area under the concentration-versus-time curve (AUC) of total plasma IgG in patients with primary immunodeficiency disease. "
2.	Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) 10/01/2010 - "This report examined data from a randomized, double-blind trial of immune globulin intravenous, 10% caprylate/chromatography purified (IGIV-C [Gamunex]; n = 59) versus placebo (n = 58) every 3 weeks for up to 24 weeks in CIDP. " 02/01/2012 - "We report a novel response-conditional crossover study design used in a Phase 3, randomized, double-blind, placebo-controlled clinical trial of intravenous 10% caprylate-chromatography purified immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy. " 09/01/2010 - "To further evaluate the long-term safety and tolerability of immune globulin intravenous, 10% caprylate-chromatography purified immune globulin intravenous in CIDP. " 02/01/2008 - "We aimed to establish whether 10% caprylate-chromatography purified immune globulin intravenous (IGIV-C) has short-term and long-term benefit in patients with CIDP. " 09/01/2010 - "Data support a favorable safety and tolerability profile for administration of immune globulin intravenous, 10% caprylate-chromatography purified as CIDP maintenance therapy. "
3.	Myasthenia Gravis 01/01/2019 - "A Phase 3 Multicenter, Prospective, Open-Label Efficacy and Safety Study of Immune Globulin (Human) 10% Caprylate/Chromatography Purified in Patients with Myasthenia Gravis Exacerbations." 01/01/2023 - "This study was conducted to determine whether immune globulin (human), 10% caprylate/chromatography purified (IGIV-C) could facilitate CS dose reduction in CS-dependent patients with MG. In this randomized double-blind placebo-controlled trial, CS-dependent patients with MG (Myasthenia Gravis Foundation of America Class II-Iva; AChR+) received a loading dose of 2 g/kg IGIV-C over 2 days (maximum 80 g/d) or placebo at week 0 (baseline). "
4.	Chronic Obstructive Pulmonary Disease (COPD) 11/01/2019 - "The aim of this study was to investigate the effect of activated ghrelin with dietary octanoic acids or medium-chain triglyceride (MCT) administration to underweight patient with chronic obstructive pulmonary disease (COPD). "
5.	Infertility (Sterility) 11/16/2006 - "In this study, six fatty acid esters (diethyl adipate, diisopropyl adipate, ethyl laurate, ethyl myristate, methyl caprylate and isopropyl palmitate) were evaluated as solvents to replace isopropyl myristate in the sterility test for ophthalmic ointments. "

Related Drugs and Biologics

1.	Intravenous Immunoglobulins (IVIG)
2.	Immunoglobulins (Immunoglobulin)
3.	Ice
4.	Fatty Acids (Saturated Fatty Acids)
5.	Solvents
6.	Ghrelin
7.	Triglycerides (Triacylglycerol)
8.	Ointments (Pastes)
9.	Immunoglobulin G (IgG)
10.	Esters

Related Therapies and Procedures

1.	Therapeutics
2.	Drug Tapering